Trial Profile

Comparing effect of lipid profile and lipid metabolism by SGLT2 inhibitor Empagliflozin in patient with type 2 diabetes.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

15 May 2021 Results assessing the effects of empagliflozin on serum markers of cholesterol absorption and synthesis in patients with type 2 diabetes, published in the International Journal of Cardiology.
16 Jun 2020 Status changed from recruiting to active, no longer recruiting, based on results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com